PubMed · 11759385
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
N Tsirulnikov, M Shohat. 2001. [Microarray technology--clinical aspects].. https://pubmed.ncbi.nlm.nih.gov/11759385/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
STALARD (selective target amplification for low-abundance RNA detection) enables isoform-level quantification of low-abundance RNAs using conventional laboratory equipment. Here, we describe steps for RNA isolation, primer design, reverse transcription, selective target amplification, and downstream analysis. The protocol couples selective pre-amplification with a quantitative reverse-transcription PCR (RT-qPCR) readout and optional nanopore sequencing. Using 1 μg input RNA and 12 pre-amplification cycles, STALARD reduces Cq values by approximately 10-12 cycles, bringing the target into a reliably quantifiable range. For complete details on the use and execution of this protocol, please refer to Jeong et al.1.
Explore the source record for details and available documents.
Explore the source record for details and available documents.